A pharmaceutical physician with 25+ years in various R&D functions including clinical research, medical affairs, pharmacovigilance, strategic product development, health economics and general management.
Experienced in all phases of clinical research including clinical pharmacology, dose finding, registration, post-launch product differentiation and surveillance. His immunotherapy expertise includes several compounds including Yervoy (ipilimumab). Prior to joining Oncos, Magnus held roles at national, European and global level at GSK, Pharmacia, Wyeth and most recently as Chief Medical Officer, Bristol Myers Squibb (Europe).
Qualified in medicine at Karolinska Institute, Stockholm, Sweden, and is a fellow of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom, and honorary lecturer in drug development at King’s College.